William Blair has the equivalent of a buy rating on the stock, as do all 13 analysts offering coverage of the stock on FactSet. The bank is one of many expecting Viking to be a takeover target, given ...
Mercer also said 64% of U.S. employers with over 20,000 employees covered weight-loss drugs in 2024, compared with 56% last ...
Many hospitals across the nation rely on the 340B program to stay afloat amid challenging financial times. But that could change significantly in the next few years.
(Reuters) - Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...
Old Town Med Spa is among those being accused of using false advertising and deceptive marketing practices to sell ...
Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing ...
As you know, our shared priority in TIME101 is to be a cash flow positive company in 2025. Reaching this goal will allow us ...
Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for ...
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...
GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...
A study using a Korean database found that COVID-19 infection raised long-term risks for various autoimmune and ...
Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback